IRREVERSIBLY-INACTIVATED PEPSINOGEN FRAGMENTS FOR MODULATING IMMUNE FUNCTION

• US 20090285776A1
• Filed: 06/18/2009
• Published: 11/19/2009
• Est. Priority Date: 11/12/2004
• Status: Active Grant

• Current Assignee: The Zhabilov Trust
• Original Assignee: The Zhabilov Trust
• Inventors: Zhabilov, Harry H.
• Granted Patent: US 8,309,072 B2
• Time in Patent Office: Days
• US Class Current: 424/85.200
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 38/488 Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG; TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP; CCATSGPCGAVMILTPHLTA; MTLTTGSGAIAPAMPPGLPPHTGAIHAPM; and NXVPVSVEGYXQITLDSITX and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Claims

1. An method of modulating immune activity comprising administering to a patient an effective amount of a composition comprising an inactivated pepsin fragment (IPF).

2. The method of claim 1, wherein the inactivated pepsin fragment (IPF) is characterized by the amino acid sequence of SEQ ID:

NO. 1.

3. The method of claim 1, wherein the inactivated pepsin fragment (IPF) is characterized by the amino acid sequence of SEQ ID:

NO. 2.

4. The method of claim 1, wherein the inactivated pepsin fragment (IPF) is characterized by the amino acid sequence of SEQ ID:

NO. 3

5. The method of claim 1, wherein the inactivated pepsin fragment (IPF) is characterized by the amino acid sequence of SEQ ID:

NO. 4.

6. The method of claim 1, wherein the inactivated pepsin fragment (IPF) is characterized by the amino acid sequence of SEQ ID:

NO. 5.

7. The method of claim 1, wherein the inactivated pepsin fragment (IPF) is characterized by the amino acid sequence of SEQ ID:

NO. 6.

8. The method of claim 2, wherein modulating immune function comprises conferring immunity against malignant human cancer cells, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 1 combined with IL-2.

9. The method of claim 3, wherein modulating immune function comprises conferring immunity against malignant human cancer cells, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 2 combined with IL-2.

10. The method of claim 4, wherein modulating immune function comprises conferring immunity against malignant human cancer cells, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 3 combined with IL-2.

11. The method of claim 5, wherein modulating immune function comprises conferring immunity against malignant human cancer cells, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 4 combined with IL-2.

12. The method of claim 6, wherein modulating immune function comprises conferring immunity against malignant human cancer cells, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 6 combined with IL-2.

13. The method of claim 7, wherein modulating immune function comprises conferring immunity against the HIV virus, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 6 combined with IL-2.

14. A method for treating HIV infection in human patients, said method comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 6 combined with IL-2

15. A therapeutic composition for treating HIV infection in human patients comprising a complex of the IPF fragment characterized by SEQ ID NO. 6 bound to human gp41.